[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607148":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":29,"studyPopulation":22,"armGroups":30,"interventions":37,"overallOfficials":45,"centralContacts":49,"locations":22,"responsibleParty":55,"collaborators":22,"id":57,"slug":22,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":22,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":22,"enrollmentInfo":65,"targetDuration":22,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":22,"overallStatus":74,"whyStopped":22,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":22},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":22},[9],{"measure":10,"description":11,"timeFrame":12},"Overall Response Rate (ORR)","ORR was defined as the proportion of patients who achieved CR or PR as their best response","1 year",[14,18],{"measure":15,"description":16,"timeFrame":17},"Overall Survival (OS)","OS was defined as time from diagnosis to death from any cause or the last follow-up","through study completion, an average of 2 years",{"measure":19,"description":20,"timeFrame":21},"Progression Free Survival (PFS)","For patients in morphologic remission, documented relapse was considered progression. Relapse following complete remission(CR) is defined as reappearance of leukemic blasts in the peripheral blood or the finding of more than 5% blasts in the BM, not attributable to another cause (eg, BM regeneration after consolidation therapy) or extramedullary relapse.","2 years]",null,{"allocation":24,"interventionModel":25,"interventionModelDescription":22,"primaryPurpose":26,"observationalModel":22,"timePerspective":22,"maskingInfo":27},"NA","SINGLE_GROUP","TREATMENT",{"masking":28,"maskingDescription":22,"whoMasked":22},"NONE","The investigators will evaluate safety and efficacy of G-Pola-GemOx as induction therapy in Refractory\u002FRelapsed Aggressive B-Cell Lymphoma. ORR(Overall response rate, progression-free survival (PFS), overall survival (OS), adverse events (AEs) will be assessed.",[31],{"label":32,"type":33,"description":34,"interventionNames":35},"Induction Therapy","EXPERIMENTAL","Patients were treated by G-Pola-GemOx as Induction Therapy",[36],"Drug: Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy",[38],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"DRUG","Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy","Patients were treated by Glofitama(Cycle 1: D8, 2.5mg, D15, 10mg; followed by the target dose of 30mg on D1 of Cycle 2-12), Polatuzumab Vedotin(1.8mg\u002Fkg iv qd d1), Gemcitabine (1000 mg\u002Fm2 iv qd d2), Oxaliplatin (100 mg\u002Fm2 iv qd d2) as induction therapy.",[32],[44],"G-Pola-GemOx",[46],{"name":47,"affiliation":5,"role":48},"Liren Qian","PRINCIPAL_INVESTIGATOR",[50,54],{"name":47,"role":51,"phone":52,"phoneExt":22,"email":53},"CONTACT","+861066947194","qlr2007@126.com",{"name":47,"role":51,"phone":22,"phoneExt":22,"email":22},{"type":48,"investigatorFullName":47,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"Associate Chief Physician, Associate Professor","100607148",false,"NCT07184788","G-Pola-GemOx in Refractory\u002FRelapsed Aggressive B-Cell Lymphoma","Glofitamab，Polatuzumab Vedotin and GemOx in Refractory\u002FRelapsed Aggressive B-Cell Lymphoma","Inclusion Criteria:\n\n* Pathologically confirmed Aggressive B-Cell Lymphoma (Including but not limited to diffuse large B-cell lymphoma, mantle cell lymphoma, Burkitt lymphoma, high-grade B-cell lymphoma, etc. according World Health Organization (WHO) classification;\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted;\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements;\n* Patient has not received chemotherapy previously.\n* Anticipated life expectancy at least 3 months\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women","ALL","14 Years",{"count":66,"type":67},80,"ESTIMATED","INTERVENTIONAL",[70],"PHASE2","The goal of this phase 2 trial is to test the safety and efficacy of G-Pola-GemOx as induction therapy in patients with Refractory\u002FRelapsed Aggressive B-Cell Lymphoma.",[73],"Aggressive B-Cell Lymphoma","NOT_YET_RECRUITING","2025-09-14",{"date":77,"type":78},"2025-09-22","ACTUAL",{"date":80,"type":67},"2025-10-01",{"date":82,"type":67},"2031-10-01",{"name":5,"class":6}]